This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Healthcare Equipment Select Industry Index CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P TMI Index CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Global BMI Index CI
Medtronic Completes Purchase Of US Medical Device Group Intersect ENT MT
Medtronic Completes Purchase of Intersect ENT MT
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from NASDAQ Composite Index CI
Hemostasis, LLC acquired Fiagon AG Medical Technologies from Intersect ENT, Inc. CI
Medtronic plc completed the acquisition of Intersect ENT, Inc.. CI
Intersect ENT, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Intersect ENT, Inc. Enters into Amendment No.1 to Facility Agreement CI
Intersect ENT, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Intersect ENT Reports Positive Data From Real-World Evidence Study of Propel Sinus Implants MT
Intersect ENT®, Inc. Announces Positive Results of Observational CI
Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures From the Firm MT
Intersect ENT, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Earnings Flash (XENT) INTERSECT ENT Reports Q3 Loss $-0.48 MT
Earnings Flash (XENT) INTERSECT ENT Posts Q3 Revenue $24.4M MT
Transcript : Intersect ENT, Inc. - Shareholder/Analyst Call
Intersect ENT, Inc. Enters into Facility Agreement CI
North American Morning Briefing : Blockbuster -3- DJ
INTERSECT ENT : SVB Leerink Downgrades Intersect ENT to Market Perform From Outperform; Price Target is $28.25 MT
North American Morning Briefing : Investors Await -3- DJ
INTERSECT ENT : BTIG Downgrades Intersect ENT to Neutral From Buy MT
INTERSECT ENT : Canaccord Genuity Downgrades Intersect ENT to Hold from Buy, Adjusts Price Target to $28.25 from $29 MT
INTERSECT ENT : Berenberg Bank Adjusts Intersect ENT Price Target to $28.25 From $18, Maintains Hold Rating MT
Chart Intersect ENT, Inc.
More charts
Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.
More about the company
  1. Stock Market
  2. Equities
  3. XENT Stock
  4. News Intersect ENT, Inc.
  5. Intersect ENT : Berenberg Bank Adjusts Intersect ENT Price Target to $28.25 From $18, Maintains Hold Rating